‘If one or two CAR-T therapies get to market it will provide impetus and momentum behind the industry’ – Dr Akshay Peer, Vice President of Sales and Account Management at TrakCel discusses the revolutionary steps that cell and gene therapies are making through their increased commercialisation.
In a field that is constantly seeing developments, Dr Peer outlines CRISPR and CAR-T therapies as forms of gene editing that can dramatically change the face of gene therapies and their use within modern medicine. He believes that as the commercialisation of these treatments increases, the regularity of their use will as well.
This is due to the surge in ‘positive public opinion’ that will arise from the successful implementation of the therapies. Dr Peer identifies the positivity that already exists around the new therapies, with ‘everyone looking at when these therapies will come to market and how much they will cost’. Although not going into detail about the financial outcome, he outlines his hope that when the public can see the lives of adults and children enhanced by using these therapies, any uncertain opinions will change to ones of optimism and confidence.
Peer acknowledges the lack of information that can exist around the new therapies due to an unfamiliarity in their usage; ‘People can sometimes get ahead of themselves and not understand completely what we’re trying to do here in this industry’. However, he is sure that this will change once there is evidence of patients who are successfully treated.
There is clearly excitement developing around the use of gene therapies, outlined by Dr Peer.
Watch the full interview, filmed at Cell Therapy Manufacturing & Gene Therapy Congress, with Dr Peer above or here.
Last week, over 850 bioprocessing professionals gathered in Amsterdam for BioProcess International European Summit 2017. Attendees moved between the exhibition hall featuring over 275 companies and nine streams covering upstream and downstream processing, cell line, vaccine manufacturing, viral safety and industry 4.0.
After a day of networking and agenda sessions, what better way to relax than a pre-King’s Day celebration with beer, gin, burgers, a DJ and LOTS of orange.
Watch some of the highlights from the event above and watch out for the full interviews with key speakers coming soon.
An Interview with Denis Bedoret of MaSTherCell
We recently sat down with Denis Bedoret, Chief BD Officier at MaSTherCell in Amsterdam at the Cell Therapy Manufacturing & Gene Therapy Congress conference to discuss the critical issues and opportunities present in the cell & gene therapy industry today.
Continue reading “Affordable Breakthrough Therapies”
With Nick Timmins, VP of Technology and Director of BridGE, CCRM
Nick Timmins, VP of Technology and Director of BridGE at CCRM sat down with us this October at Biotech Week Boston to discuss the collaboration efforts between CCRM and GE Healthcare, what issues have been encountered along the way, his experience working with start-ups, and much more. When initially outlining the GE collaboration, Nick mentions, “A key focus of this collaboration is really about identifying where gaps are in the field for cell and gene therapy manufacturing solutions both on the process side of things as well as the technologies that we utilize to enable those processes.” watch the full interview below to hear his complete thoughts on these pressing issues and the importance of this collaboration on the cell and gene therapy industry.